The U.S. CRISPR and Cas genes market was valued at USD 1.01 billion in 2024 and is projected to hit USD 5.11 billion by 2034, growing at a CAGR of 17.6% (2025–2034).
Biomedical applications held the largest share in 2024, while agriculture is expected to see major growth.
Leading players include CRISPR Therapeutics, Intellia, Editas Medicine, Beam Therapeutics, Mammoth Biosciences, and Caribou Biosciences

Link